Queensland is fast becoming Australia’s premier investment destination for biomedical and health industry projects. We have a dynamic and diverse economy supported by a pro-business government, sophisticated infrastructure and a skilled workforce.
QIC is a trusted investment manager and adviser providing risk adjusted returns for the clients we serve. As one of Australia’s leading institutional investment managers, we deliver alternative real asset solutions across infrastructure, real estate, private debt, private capital and natural capital in addition to a liquid market offering for our 125 Australian and global clients. We also act as the Queensland Government’s independent investment advisor, managing a fully-funded Defined Benefit scheme and the Queensland Future Fund both of which delivers on the State’s long-term investment objectives. We have US$65bn in assets under management (as at 31 March 2023) and are headquartered in Brisbane, Australia, with offices in Sydney, Melbourne, New York, San Francisco and London.
Sanofi Australia is part of a global healthcare organisation that employs over 100,000 people across 170 countries. Our purpose is to bring hope, relief and cures to patients with the medicines and vaccines that we make. Established in Australia in 1980, our heritage spans 100 years, pioneering medicine across broad therapeutic areas including diabetes, cardiovascular disease, influenza, oncology, immunology, rare diseases and rare blood disorders. Today in Australia we are a leading supplier of diabetes medicines and vaccines. We strive to provide quality vaccination coverage from infectious diseases to all Australians. 95% of young Australian’s will have had a Sanofi vaccine by age five, and one in four Australians has had one of our flu vaccines. Due to our global manufacturing network and dedicated local team of over 700 people, we reliably supply quality innovative vaccines, medicines and healthcare solutions, throughout the country, enabling those in rural and remote locations to access our treatments. Our breakthrough science, technology and unique collaborations allow us to accelerate access to scientific innovation and benefit the lives of patients who depend on us. From the many with rare conditions, the millions with chronic disease to those seeking protection from infectious disease. In collaboration with clinicians, our clinical trials are an important phase of our research, and annually supports access for over 500 Australians to many scientific innovations including those for atopic dermatitis, multiple sclerosis and haemophilia. Inclusion and diversity are at the heart of our culture, allowing our people to feel heard, valued and respected. We embrace news ways of thinking, which is integral to innovation, and allows us to better understand, connect and meet the health needs of people in Australia.
Springfield City Group develops commercial, educational, healthcare, and residential real estate projects, with a vision of making Greater Springfield a sustainable regional city and services hub by 2030. BioPark Australia is to create a place where multiple biologic industries (Therapeutics, Vaccines, Med Tech, Diagnostics will co-locate and grow. Central to the BioPark will be its provision of the complete suite of necessary components and reagents for these industries. Future-proofing is built-in with staged expansion sites available to users.
The Translational Research Institute (TRI) is an Australian initiative focused on advancing medical research from the laboratory to the community. Combining clinical and translational research, TRI aims to enhance detection, diagnosis, and treatment methods for various health conditions, ultimately improving patient outcomes. Their work spans across different areas, including cancer, autoimmune diseases, and more, with a focus on developing innovative treatments and diagnostics that can be translated into better healthcare practices.
The University of Southern Queensland (USQ) is a young, dynamic university. USQ has campuses in the regional centres of Toowoomba, Springfield and Ipswich. USQ is internationally recognised for delivering practical, world-class research that delivers high-impact solutions.
UniQuest is Australia’s leading commercialisation entity, specialising in commercialising the intellectual property of The University of Queensland, a global top 50 university. Uniquest benchmarks in the top tier of technology transfer worldwide.
USC Clinical Trials, in collaboration with healthcare professionals in the Sunshine Coast and Moreton Bay, offers expert services for all phases of drug and device clinical trials. They have a wide range of therapeutic areas in their expanding portfolio. The team comprises experienced Principal and Sub-Investigators who are matched to each study based on their expertise. With over 40 completed and ongoing studies across phases I to IV, USC Clinical Trials has the necessary experience to support your research.
A young, fresh university driven by an unwavering belief that community and culture is just as important as a world-class education, delivered by world-class educators. We may not be the biggest university, but we’re growing fast, and doing big things. Like ground-breaking research, championing sustainability, producing gold-winning athletes and award-winning alumni. Our first campus, on the Sun
The $70 million UQ Centre for Clinical Research (CCR) at the Royal Brisbane and Women's Hospital (RBWH) is focused on improving people's lives through patient-orientated research. Offer state-of-the-art facilities and bring together leading health professionals, clinicians and scientists from around the globe.
The University of Queensland is one of Australia’s leading research and teaching institutions. We strive for excellence through the creation, preservation, transfer and application of knowledge. For more than a century, we have educated and worked with outstanding people to deliver knowledge leadership for a better world.UQ is consistently ranked among the world's top 50 universities. In the 2022 Aggregate Ranking of Top Universities, UQ ranked 2nd in Australia and 42nd in the world.
Vaxxas is commercialising novel technology that dramatically enhances the performance of existing next-generational vaccines. Their delivery platform enables robust immune system activation by targeting vaccine components to the abundant immunological cells immediately below the skin’s surface. Vaxxas’ proprietary Nanopatch™ technology aims to provide an optimised, differentiated needle-free vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy.
%20(003).jpg){kind=logo}
.png)
